Last reviewed · How we verify
NCT05187169
Food Effect of VS-6766 in Healthy Adult Subjects
Phase 1 trial testing VS-6766 in Food Effect in 18 participants. Completed in 12 April 2022.
12 April 2022
Quick facts
| Lead sponsor | Verastem, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 16 December 2021 |
| Primary completion | 12 April 2022 |
| Estimated completion | 12 April 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- VS-6766 — full drug profile →
Conditions studied
- Food Effect — all drugs for Food Effect →
Sponsor
Verastem, Inc. — full company profile →
Who can join
Adults 18 to 55, any sex, with Food Effect. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An Open-Label, 2-Way, 2-Period Crossover Study of Orally Administered VS-6766 in Healthy Adult Subjects to Determine the Effect of Food on the Pharmacokinetics of VS-6766
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Bahar ME, Kim HJ, Kim DR. · · 2023 · cited 519× · PMID 38105263 · DOI 10.1038/s41392-023-01705-z
Verify or expand the search:
- PubMed search for NCT05187169
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VS-6766
Trials testing the same drug.
- NCT05608252 — VS-6766+Abema+Fulv in Met HR+/HER- BC · Phase 1, PHASE2 · recruiting
- NCT03875820 — Phase I Trial of Defactinib and VS-6766. · Phase 1 · active not recruiting
- NCT02407509 — Phase I Trial of VS-6766 Alone and in Combination With Everolimus · Phase 1 · completed
Other recruiting trials for Food Effect
Currently open trials in the same condition.
- NCT07098663 — Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes · Phase 2 · recruiting
Other Verastem, Inc. trials
Trials by the same sponsor.
- NCT06072781 — A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer · Phase 3 · recruiting
- NCT05669482 — Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer · Phase 1, PHASE2 · active not recruiting
- NCT05375994 — Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients · Phase 1, PHASE2 · active not recruiting
- NCT04620330 — A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer · Phase 2 · completed
- NCT02004028 — Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05187169 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Verastem, Inc.
- Last refreshed: 10 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05187169.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing